Syndax (SNDX) Q2 2026 Earnings Call Transcript
Syndax (SNDX) discussed its Q2 2026 earnings call, focusing on menin inhibitor Revuforj and axatilimab-related pipeline. Revuforj net revenue was $55 million, up 12% QoQ, with about 1,500 prescriptions, up 15% QoQ. Niktimvo Q2 net revenue rose to $60 million, up 67% YoY. The company reiterated expectations for Revuforj peak US net revenue above $2 billion.
How this was made
The 30-second read
Why it matters
The most tradable elements are the reported quarterly commercial metrics (Revuforj revenue and prescriptions, Niktimvo YoY growth) and the timing of upcoming data readouts that could affect valuation expectations for future indications.
Market read
Traders can use the disclosed quarterly commercial metrics and the stated 2H and Q4 data timing to frame near-term sentiment and catalyst-driven positioning.
What to watch
The excerpt does not provide detailed cost, margin, cash runway, or full pipeline risk updates; investors may discount the commercial story without those financial specifics.
Background
This is a Q2 2026 earnings call transcript focused on commercial performance of Revuforj and Niktimvo, plus pipeline updates for Revumenib, axatilimab, and early-stage assets.
Ticker impact
Syndax reports Q2 2026 Revuforj net revenue of $55M and prescriptions of about 1,500, plus growth drivers tied to treatment duration and new patient starts.
Near-term sentiment likely positive if investors focus on sustained double-digit Revuforj growth and the stated confidence in Revuforj’s forward trajectory.
This is a primary earnings-call disclosure with multiple quantitative datapoints (revenue, prescriptions, YoY growth) and forward-looking catalyst timing (2H data at major meetings, Q4 publication), but the excerpt does not include full guidance, cash flow, or explicit consensus comparisons.
Market effects
Reinforces investor appetite for commercial-stage oncology drugs targeting menin-dependent AML and related indications, potentially supporting the broader hematology-oncology sentiment.
Limited direct regional spillover; primarily US biotech/healthcare sentiment.
Global relevance mainly through multinational trial sites and major medical meeting readouts referenced for 2H and Q4.
Counterpoint
Growth narrative may be sensitive to quarter-to-quarter fluctuations in new patient starts and to how durable treatment duration gains prove versus prior quarters.
Key entities
- companySyndax Pharmaceuticals
Subject of the earnings call transcript, discussing Q2 2026 commercial results and pipeline catalysts.
- productRevuforj (revumenib)
Menin inhibitor highlighted for double-digit net revenue and prescription growth, plus expansion across NPM1 and KMT2A.
- productNiktimvo (axatilimab)
Chronic GVHD therapy discussed with Q2 net revenue growth and adoption trends.
- pipeline_programaxatilimab
Phase II catalysts referenced for IPF and frontline chronic GVHD expected in Q4.
- pipeline_programRevumenib
Additional practice-informing evidence expected in 2H at major medical meetings, plus Q4 publication in NUP98 rearranged acute leukemia.
